Breast Cancer

, Volume 27, Issue 1, pp 9–16 | Cite as

The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition

  • Chikako YamauchiEmail author
  • Michio Yoshimura
  • Kenji Sekiguchi
  • Yasushi Hamamoto
  • Naomi Nakajima
  • Naoko Sanuki
  • Etsuyo Ogo
  • Masahiko Oguchi
  • Shigehira Saji
  • Hiroji Iwata
Special Article



The Japanese Breast Cancer Society (JBCS) Clinical Practice Guideline was revised in 2018. This article describes the revise points in the section on radiation therapy (RT).

Methods and materials

The JBCS formed task force to update the JBCS Clinical Practice Guideline 2015 edition. Background questions (BQs) deal with standard treatments of breast cancer in clinical practice. Clinical questions (CQs) highlight the important treatments in which controversy remains. The task force for RT section addressed the 10 BQs, the 10 CQs, and the 4 Future reseach questions (FQs). For each CQ, systematic literature reviews and meta-analyses were conducted, and recommendations, strength of recommendation and strength of evidence were determined according to the protocol in Morizane et al. (Minds Handbook for Clinical Practice Guideline Development, 2014).


The recommendations, the strength of recommendation and the strength of evidence were determined based on the systematic literature reviews and the meta-analyses for each CQ.


The JBCS updated the Clinical Practice Guideline. RT represents a significant portion of the breast cancer treatment, and these recommendations regarding RT will be useful in individualized, shared decision making between physicians and patients.



We would like to acknowledge the contributions of all member of The Japanese Breast Cancer Society Clinical Practice Guidelines Committee, all members of the systematic reviewer, Fujimi Kawai and Shinichi Abe of Japan Medical Library Association, Prof. Masahiro Yoshida of International University of Health and Welfare, and Kanehara Publishing Co., Ltd.,Hitomi Sasaki and Kazuyo Uno.

Compliance with ethical standards

Conflict of interest

Chikako Yamauchi, Michio Yoshimura, Kenji Sekiguchi, Yasushi Hamamoto, Naomi Nakajima, Naoko Sanuki, Etsuyo Ogo, and Masahiko Oguchi have no conflict of interest. Hiroji Iwata reports grants and personal fees from Chugai, personal fees from AstraZeneca, personal fees from Daiichi Sankyo, grants and personal fees from Novartis, grants from MSD, grants and personal fees from Lilly, personal fees from Kyowa Hakko Kirin, personal fees from Pfizer, during the conduct of the study. However, Dr. Iwata confirms that the total fee from each company is not over the limited fee determined by JBCS. Shigehira Saji reports grants and personal fees (honoraria for lectures) from Eisai, grants and personal fees from Chugai, grants and personal fees from Astra Zeneca, grants and personal fees from Takeda, grants and personal fees from Novartis, grants and personal fees from Taiho, personal fees from Kyowahakko Kirin, personal fees from Pfizer, personal fees from Daiichi Sankyo, grants and personal fees from Nihon Kayaku, grants from Ono, outside the submitted work; Dr. Saji is executive board member of JBCRG and JBCS.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Morizane T, Yoshida M, Kojimahara N, editors. Minds handbook for clinical practice guideline development. Tokyo: Igaku-shoin; 2014.Google Scholar
  2. 2.
    Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20.CrossRefGoogle Scholar
  3. 3.
    Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94.CrossRefGoogle Scholar
  4. 4.
    Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;81(1):59–68.CrossRefGoogle Scholar
  5. 5.
    Nozaki M, Kagami Y, Shibata T, Nakamura K, Ito Y, Nishimura Y, et al. A primary analysis of a multicenter, prospective, single-arm, confirmatory trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906. Jpn J Clin Oncol. 2019;49(1):57–62.CrossRefGoogle Scholar
  6. 6.
    Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, et al. Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018;8(3):145–52.CrossRefGoogle Scholar
  7. 7.
    Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1):47–56.CrossRefGoogle Scholar
  8. 8.
    Hickey BE, Lehman M, Francis DP, See AM. Partial breast irradiation for early breast cancer. Cochrane Database Syst Rev. 2016;7:CD007077.PubMedGoogle Scholar
  9. 9.
    Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307–16.CrossRefGoogle Scholar
  10. 10.
    Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317–27.CrossRefGoogle Scholar
  11. 11.
    EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35.CrossRefGoogle Scholar
  12. 12.
    Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 2017;35(15):1641–9.CrossRefGoogle Scholar
  13. 13.
    Matzinger O, Heimsoth I, Poortmans P, Collette L, Struikmans H, Van Den Bogaert W, et al. Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925). Acta Oncol. 2010;49(1):24–34.CrossRefGoogle Scholar
  14. 14.
    Warren LE, Miller CL, Horick N, Skolny MN, Jammallo LS, Sadek BT, et al. The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. Int J Radiat Oncol Biol Phys. 2014;88(3):565–71.CrossRefGoogle Scholar
  15. 15.
    Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337(14):949–55.CrossRefGoogle Scholar
  16. 16.
    Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353(9165):1641–8.CrossRefGoogle Scholar
  17. 17.
    Hennequin C, Bossard N, Servagi-Vernat S, Maingon P, Dubois JB, Datchary J, et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2013;86(5):860–6.CrossRefGoogle Scholar
  18. 18.
    Thorsen LB, Offersen BV, Dano H, Berg M, Jensen I, Pedersen AN, et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2016;34(4):314–20.CrossRefGoogle Scholar
  19. 19.
    Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol. 2012;30(32):3960–6.CrossRefGoogle Scholar
  20. 20.
    McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007;68(4):1004–9.CrossRefGoogle Scholar
  21. 21.
    Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79(4):965–76.CrossRefGoogle Scholar
  22. 22.
    Wu JS, Wong RK, Lloyd NS, Johnston M, Bezjak A, Whelan T. Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases—an evidence-based practice guideline. BMC Cancer. 2004;4:71.CrossRefGoogle Scholar
  23. 23.
    Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, Hirota S, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007;68(5):1388–95.CrossRefGoogle Scholar
  24. 24.
    Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401–9.CrossRefGoogle Scholar
  25. 25.
    Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–44.CrossRefGoogle Scholar
  26. 26.
    Shim SJ, Park W, Huh SJ, Choi DH, Shin KH, Lee NK, et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05). Int J Radiat Oncol Biol Phys. 2014;88(1):65–72.CrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2019

Authors and Affiliations

  • Chikako Yamauchi
    • 1
    Email author
  • Michio Yoshimura
    • 2
  • Kenji Sekiguchi
    • 3
  • Yasushi Hamamoto
    • 4
  • Naomi Nakajima
    • 5
  • Naoko Sanuki
    • 6
  • Etsuyo Ogo
    • 7
  • Masahiko Oguchi
    • 5
  • Shigehira Saji
    • 8
  • Hiroji Iwata
    • 9
  1. 1.Department of Radiation OncologyShiga General HospitalMoriyama-shiJapan
  2. 2.Department of Radiation Oncology and Image-applied TherapyKyoto University Graduate School of MedicineKyotoJapan
  3. 3.Department of Radiation OncologySonoda-kai Radiation Oncology ClinicTokyoJapan
  4. 4.Department of RadiologyEhime University HospitalToonJapan
  5. 5.Radiation Oncology Department, The Cancer Institute HospitalJapanese Foundation for Cancer ResearchTokyoJapan
  6. 6.Radiation Therapy DepartmentMie Prefectural General HospitalYokkaichiJapan
  7. 7.Department of RadiologyKurume University School of MedicineKurumeJapan
  8. 8.Department of Medical OncologyFukushima Medical UniversityFukushimaJapan
  9. 9.Department of Breast OncologyAichi Cancer Center HospitalNagoyaJapan

Personalised recommendations